Director Christopher Twomey filed a Form 144 notice with the SEC on October 27, 2026, disclosing a proposed sale of 1,700 shares of Tandem Diabetes Care, Inc. common stock acquired through the exercise of stock options.

Key Highlights

  • Filer and role: Christopher Twomey, a Director of Tandem Diabetes Care, Inc., filed the notice.
  • Shares proposed for sale: 1,700 shares of common stock, with an aggregate market value of $32,130.00.
  • Shares outstanding: 69,578,707 shares of common stock reported as outstanding.
  • Acquisition method: The 1,700 shares were acquired on October 27, 2026, through the exercise of stock options from the issuer, with cash payment.
  • Approximate sale date: October 27, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services, on NASDAQ.
  • Rule 10b5-1 plan: The filing indicates a plan adoption date of May 19, 2026.
  • Prior three-month sales: The filing reports nothing to report for securities sold during the past three months.

Twomey's Proposed Share Sale Under Rule 144 at Tandem Diabetes Care

According to the Form 144 filing, Christopher Twomey, a Director of Tandem Diabetes Care, Inc. (NASDAQ:TNDM), submitted notice of a proposed sale of 1,700 shares of the company's common stock. The filing was submitted on October 27, 2026, and lists an approximate sale date of the same day. The aggregate market value of the shares is stated as $32,130.00, and the total shares of common stock outstanding are reported as 69,578,707.

The filing discloses that the 1,700 shares were acquired on October 27, 2026, through the exercise of stock options granted by the issuer, with full payment made in cash on the same date. The broker identified for the proposed sale is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, and the transaction is to occur on NASDAQ.

The notice further discloses that Twomey is relying on a Rule 10b5-1 trading plan, with a plan adoption date of May 19, 2026. The filing also states that no securities of Tandem Diabetes Care were sold by Twomey during the past three months, listed under the "Securities Sold During The Past 3 Months" section as "Nothing to Report." The issuer's address is listed as 12400 High Bluff Drive, San Diego, California 92130.

What Was Disclosed

Director Christopher Twomey filed a Form 144 notice proposing to sell 1,700 shares of Tandem Diabetes Care common stock, acquired via stock option exercise on October 27, 2026, with an aggregate market value of $32,130.00, under a Rule 10b5-1 plan adopted May 19, 2026.